



EVIANA HEALTH CORPORATION

5728 E. Boulevard
Vancouver, BC, V6M 4M4

Eviana Announces Proposed \$10 Million Debenture Offering

VANCOUVER, BC, AND TORONTO, ON, September 13th, 2018 –Eviana Health Corporation (the “**Company**” or “**Eviana**”) (CSE: EHC) (OTC: EVNMF) – The Company is pleased to announce that it has executed a term sheet for a CAD\$10,000,000 private placement debenture offering (the “**Debenture Offering**”) with Organigram Holdings Inc. (“**Organigram**”) (TSX VENTURE: OGI, US OTCQB: OGRMF) and an institutional strategic investor each participating as to 50% of the offering. The Debenture Offering is to be comprised of 10,000 debenture units (the “**Debenture Units**”) of the Company, each consisting of (i) \$1,000 principal amount of senior unsecured convertible debentures of the Company (the “**Debenture**”); and (ii) one half of one Common Share (“**Common Shares**”) purchase warrant of the Company (each whole such purchase warrant, a “**Warrant**”). Each full Warrant shall be exercisable by the holder thereof for 870 Common Shares in the capital of the Company (the “**Warrant Shares**”) at an exercise price per Warrant Share of \$1.30 for a period of 24 months from the closing date of the Transaction. The Debentures will be convertible into that number of Eviana Common Shares computed on the basis of the principal amount of the Debentures divided by the conversion price of \$1.15 per share at the holder’s option, or upon mandatory conversion at the request of Eviana in the event that at any time following four months plus one day following the Closing, for any ten consecutive trading days, the daily volume weighted average closing price of the Eviana Common Shares on the CSE is greater than \$2.15.

The Debentures shall bear interest at a rate of 10.0% per annum from the date of issue, payable semi-annually in arrears on June 30 and December 31 of each year, commencing December 31, 2018. Interest shall be computed on the basis of a 360-day year composed of twelve 30-day months. The December 31, 2018 interest payment will represent accrued interest for the period from the Closing Date to December 31, 2018. Upon conversion of the Debentures, the holder shall also receive a cash payment equal to the additional interest amount that such holder would have received up to the date of conversion.

The Debenture Offering is expected to be completed on or about September 27, 2018, or such earlier or later date as the Strategic Investor, Organigram and the Company may determine.

Board Representation

On closing of the Debenture Offering, Organigram shall be granted board representation rights, pursuant to which the Company will agree to include one Organigram designated candidate for election to the board of directors of the Company and to solicit support for such candidate at all shareholder meetings at which directors are to be elected.

Offtake Sales Agreement

Organigram shall have the right, but not the obligation, to purchase up to and including 25% (the “**Offtake Percentage**”) of the Company’s (on a consolidated basis) annual CBD oil (or a comparable form including, but not limited to, CBD crystals) at 95% of the agreed raw CBD oil (or equivalent thereof) wholesale market price for a period of 5 years from the date on which the CBD oil (or equivalent thereof) is first made commercially available by the Company for wholesale (subject to final agreement on terms between management of both companies).

Haywood Securities Inc. is acting as the Company’s lead agent for the Debenture Offering.

The securities proposed to be issued in connection with the Debenture Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States unless an exemption from registration is available. This news release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Eviana or Organigram in any jurisdiction.

For further information, please contact:

Eviana Health Corporation:
Sydney Au, Chief Financial Officer
Avram Adizes, Chief Executive Officer
Patrick Brown, V.P. Bus Dev & Corp Comm
(604) 780-3311
info@eviana.com

About Eviana Health Corporation

Eviana Health Corporation is a Canadian Securities Exchange listed company that was established with the aim of delivering customized consumer health care products using natural hemp strains of cannabis sativa for cannabinoid-based topical creams and products and cosmeceutical and nutraceutical merchandise.

This news release contains forward-looking information about the Company which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors - including the availability of funds, consummation of definitive documentation, the results of financing efforts, crop yields - that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.